An etomidate artificial hapten, artificial antigen, and preparation method and application thereof
By chemically modifying and coupling etomidate, artificial antigen is generated, the problem of rapid accuracy of etomidate detection in the prior art is solved, efficient etomidate detection is achieved, and high affinity and strong specificity are obtained. Antibody.
Patent Information
- Application Number
- CN202310334342.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-31
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-03-31
AI Technical Summary
The prior art cannot detect etomidate quickly and accurately, and immunoassays are difficult to directly induce specific antibodies to small-molecular compounds such as etomidate, and lack efficient artificial antigens.
By chemically modifying etomidate, the active groups are introduced and coupled to the carrier protein, artificial haptens and artificial antigens are generated, ensuring that their characteristic structure is retained and recognized by the immune system, and high-affinity and strong specificity are prepared. .
Fast and accurate etomidate detection is achieved, and the antibody titer obtained is as high as 1:90,000, which is used for immunoassay and analysis, meeting the requirements of modern testing.
Smart Images

Figure CN116354888B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biochemical engineering, and specifically relates to an etomidate artificial hapten, an artificial antigen, and a preparation method and application thereof. Background Art
[0002] Etomidate is a non-barbiturate intravenous short-acting hypnotic and one of the commonly used drugs for anesthesia induction. Etomidate has a 30-year history of clinical application and has a strong inhibitory effect on the central nervous system through intravenous injection. Its duration of action can be prolonged accordingly with increasing doses, and it has little effect on the respiratory and circulatory systems. It can cause short-term respiratory depression, a slight decrease in systolic blood pressure, and a slightly increased heart rate. It has no histamine release effect and is suitable for general anesthesia induction and can also be used for short-term surgical anesthesia.
[0003] For regulatory purposes, a rapid assay for etomidate needs to be developed.
[0004] At present, the detection of etomidate mainly relies on high performance liquid chromatography (HPLC), gas chromatography (GC), thin layer chromatography (TLC), mass spectrometry (MS), etc. However, these methods have the disadvantages of expensive instruments, time-consuming detection, and the need for professional technicians to operate, and cannot meet the requirements of modern detection for rapidity and accuracy.
[0005] Immunoassay can make up for all the above shortcomings. Immunoassay is an analytical method that uses antigen-antibody specific binding reactions to detect various substances (drugs, hormones, proteins, microorganisms, etc.). The key to establishing an immunoassay for small molecule compounds is to be able to produce antibodies with high affinity and high specificity for small molecule compounds. However, since most small molecule compounds (molecular weight less than 1000), including etomidate, are not immunogenic, that is, they lack T cell epitopes and cannot directly induce the animal body to produce specific antibodies, small molecules are called haptens. Through appropriate chemical modification, a connecting arm with an active group at the end is added to a certain position of the hapten molecular structure, and then combined with a macromolecular carrier to generate a hapten-carrier conjugate (i.e., artificial antigen). Artificial antigens can indirectly induce the proliferation and differentiation of B cells with the help of T cell epitopes, and then produce specific antibodies. Therefore, the synthesis of efficient artificial antigens is the premise and key to ensure immunoassay.
[0006] There is no related report on artificial hapten and artificial antigen of etomidate in the prior art. Summary of the invention
[0007] The invention provides an etomidate artificial hapten, which retains the characteristic structure of etomidate to the greatest extent, has an active group that can be coupled with a carrier protein, and can be used as an antigenic determinant.
[0008] In order to achieve the above technical objectives, the present invention is implemented through the following technical solutions:
[0009] The first object of the present invention is to provide an artificial hapten of etomidate, the molecular structure of which is shown in I:
[0010]
[0011] The second object of the present invention is to provide a method for preparing the etomidate artificial hapten, the method comprising the following steps:
[0012] (1) performing a hydrolysis reaction between etomidate and an alkaline solution, and then adjusting the pH value to an acidic state to obtain a compound represented by formula A;
[0013] (2) the compound represented by formula A is subjected to an esterification reaction with methanol to obtain a compound represented by formula B;
[0014] (3) The compound represented by formula B is subjected to a reduction reaction with lithium aluminum hydride to obtain a compound represented by formula C;
[0015] (4) The compound represented by formula C is subjected to substitution reaction with succinic anhydride to prepare the artificial hapten of etomidate represented by formula I.
[0016] The reaction formula of the method is as follows:
[0017]
[0018] Furthermore, in step (1), the alkaline solution is preferably an aqueous sodium hydroxide solution;
[0019] In the step (2), the catalyst for the esterification reaction is concentrated sulfuric acid.
[0020] In the step (3), the molar ratio of the compound represented by formula B to lithium aluminum hydride is preferably 1:1.5-3, more preferably 1:2-3.
[0021] In the step (4), the molar ratio of the compound represented by formula C to succinic anhydride is preferably 1:1.5 to 2.5, more preferably 1:2.
[0022] Further, the method is preferably carried out according to the following steps:
[0023] (1) dissolving etomidate in tetrahydrofuran and anhydrous methanol, adding 1N sodium hydroxide aqueous solution, rapidly stirring at room temperature, and performing a hydrolysis reaction for 4 to 6 hours. After the reaction, the pH of the reaction solution is adjusted to 4 to 5, and the obtained reaction solution is post-treated to obtain a compound represented by formula A;
[0024] The molar ratio of etomidate to NaOH in 1N sodium hydroxide aqueous solution is generally 1:10-50;
[0025] The volume amount of anhydrous methanol is generally 10 to 30 mL / g based on the mass of etomidate;
[0026] The volume amount of tetrahydrofuran is generally 10 to 30 mL / g based on the mass of etomidate;
[0027] After the reaction is completed, 1N hydrochloric acid is generally used to adjust the pH of the reaction solution to 4-5.
[0028] The post-treatment step of the reaction solution in step (1) is generally as follows: after adjusting the pH of the reaction solution to 4-5, extracting with dichloromethane, combining the organic phases, drying, filtering, and distilling off the solvent from the filtrate to obtain the compound shown in formula A
[0029] (2) adding the compound represented by formula A to anhydrous methanol, using 98% by mass concentrated sulfuric acid as a catalyst, heating to 65-70° C. under reflux for esterification reaction, the reaction time is 15-20 hours, and after the reaction, the reaction solution is post-treated to obtain the compound represented by formula B;
[0030] The volume amount of anhydrous methanol is generally 40 to 100 mL / g based on the mass of the compound represented by formula A;
[0031] The volume usage of the 98% by mass concentrated sulfuric acid is generally 1 to 3 mL / g, preferably 1.5 mL / g, based on the mass of the compound represented by formula A.
[0032] The post-treatment step of the reaction solution in step (2) is generally as follows: after the reaction is completed, the reaction solution is adjusted to a pH value of 7.5 to 8 with sodium bicarbonate, filtered, the filtrate is evaporated to remove the solvent, tetrahydrofuran is added for extraction, dried, filtered, and the filtrate is evaporated to remove the solvent to obtain the compound represented by formula B.
[0033] (3) Under nitrogen protection, the compound represented by formula B and lithium aluminum hydride are subjected to reduction reaction in anhydrous tetrahydrofuran solvent, and the reaction mixture is heated to 65-70° C. and refluxed for 15-25 hours. After the reaction, the reaction solution is post-treated to obtain the compound represented by formula C;
[0034] The molar ratio of the compound represented by formula B to lithium aluminum hydride is preferably 1:1.5-3, more preferably 1:2-3.
[0035] The volumetric dosage of tetrahydrofuran is generally 80 to 150 mL / g based on the mass of the compound represented by formula B.
[0036] The post-treatment step of the reaction solution in step (3) is generally as follows: after the reaction is completed, the reaction solution is adjusted to a pH of 8 to 9 with a 30 wt % sodium hydroxide aqueous solution, filtered, and the filtrate is evaporated to remove the solvent and dried to obtain the compound represented by formula C;
[0037] (4) the compound represented by formula C is dissolved in anhydrous pyridine, succinic anhydride is added, and the mixture is heated to 100-105° C. and refluxed for 15-30 hours. After the reaction, the reaction solution is post-treated to obtain the etomidate artificial hapten represented by formula I;
[0038] The molar ratio of the compound represented by formula C to succinic anhydride is preferably 1:1.5 to 2.5, more preferably 1:2.
[0039] The volumetric dosage of the pyridine is generally 100 to 150 mL / g based on the mass of the compound represented by Formula C.
[0040] The post-treatment step of the reaction solution in step (4) is generally as follows: after the reaction is completed, the reaction solution is distilled under reduced pressure to remove the solvent, a small amount of anhydrous ethanol is used to dissolve the residue, and thin layer chromatography is used to purify the residue to obtain the etomidate artificial hapten shown in formula I.
[0041] The chromatographic liquid used in the thin layer chromatography method is a mixed solvent of 95% ethanol, 1,4-dioxane, dichloromethane and ammonia water in a volume ratio of 8:1:10:1, and the product Rf=0.4.
[0042] The present invention introduces a connecting arm into the hydrocarbon chain position of etomidate through the above method. The introduction of the connecting arm into the modification site can retain the characteristic structure of etomidate to the greatest extent, and the modification site is as far away from the characteristic functional group of etomidate as possible, so that the characteristic part of etomidate is exposed to the outside to the greatest extent, so as to avoid interference with the specific antigen determinant cluster and be recognized by the immune body to the greatest extent.
[0043] Compared with the use of a circular connecting arm, the connecting arm used in the present invention is chain-shaped and has an appropriate length, which ensures that the etomidate hapten small molecule can be fully exposed on the surface of the artificial antigen and reduces the recognition of the connecting arm by T cells during immunization as much as possible. In this way, the antibodies obtained by immunization have stronger specificity and affinity for etomidate.
[0044] The third object of the present invention is to provide an etomidate artificial antigen, whose molecular structure is shown in II:
[0045]
[0046] In formula (II), BGG is bovine immunoglobulin G.
[0047] The fourth object of the present invention is to provide a method for preparing the etomidate artificial antigen, which comprises combining the etomidate artificial hapten shown in formula I with bovine immunoglobulin G by a mixed anhydride method to obtain the etomidate artificial antigen shown in formula II.
[0048] Furthermore, when the mixed acid anhydride method is used to prepare the etomidate artificial antigen, the method comprises the following steps:
[0049] (a) the artificial hapten etomidate of formula I, isobutyl chloroformate and triethylamine are reacted in DMF solvent at 0 to 5° C. (generally in an ice bath) for 2 to 4 hours under stirring, and after the reaction is completed, the supernatant is collected by centrifugation;
[0050] The molar ratio of the etomidate artificial hapten represented by formula I, isobutyl chloroformate and triethylamine is 1:1-1.5:1-1.5, preferably 1:1.2-1.3:1.1-1.2.
[0051] The volume usage of the DMF solvent is 30-80 mL / g based on the mass of the etomidate artificial hapten shown in Formula I.
[0052] (b) adding the supernatant dropwise to the bovine immunoglobulin solution, and allowing the resulting mixture to stand at 3-5° C. overnight (usually for 15-24 hours), dialyzing and centrifuging to obtain the supernatant to obtain the etomidate artificial antigen represented by formula II.
[0053] Furthermore, the bovine immunoglobulin G solution of the present invention is prepared by dissolving bovine immunoglobulin G in 0.01 M PBS buffer solution with a pH of 7.2-7.4.
[0054] In the step (b), the concentration of the bovine immunoglobulin G solution is 5 mg / mL, and the volume ratio of the supernatant to the bovine immunoglobulin G solution is 1:5-6.
[0055] The invention selects bovine gamma globulin (BGG) as a macromolecular carrier, which has the following advantages compared with bovine serum albumin (BSA): 1. the purity of bovine gamma globulin is generally higher than that of bovine serum albumin, and a small amount of antibody residues in most bovine serum albumins are not conducive to the stability of immune experiments; 2. bovine serum albumin has too many free amino acids and has too high immunogenicity, which will produce a lot of antibodies against bovine serum albumin, resulting in cross-reaction between antigens and antibodies; 3. the etomidate artificial antigen formed by combining bovine gamma globulin with the etomidate artificial hapten has better specificity of anti-etomidate bodies obtained by animal immunization.
[0056] The present invention also provides application of the etomidate artificial antigen in preparing anti-etomidate antibodies.
[0057] The fifth object of the present invention is to provide the use of the etomidate artificial hapten or etomidate artificial antigen in the preparation of anti-etomidate antibodies
[0058] The sixth object of the present invention is to provide an anti-etomidate antibody, which is a globulin obtained by immunizing animals with the etomidate artificial antigen and can undergo a specific immune reaction with etomidate.
[0059] A seventh object of the present invention is to provide use of the anti-etomidate antibody in detecting etomidate.
[0060] The eighth object of the present invention is to provide a reagent for detecting etomidate, wherein the reagent comprises the anti-etomidate antibody.
[0061] The ninth object of the present invention is to provide a kit for detecting etomidate, wherein the kit comprises the anti-etomidate antibody.
[0062] The experiment found that the titer of the immune serum obtained by immunizing New Zealand white rabbits with the artificial etomidate antigen was 1:90000, indicating that the artificial etomidate antigen of the present invention can be used to immunize and obtain anti-etomidate antibodies with high affinity, high sensitivity and strong specificity, and the anti-etomidate antibodies can be used for immunodetection and analysis of etomidate.
[0063] Compared with the prior art, the present invention has the following beneficial effects:
[0064] The artificial etomidate hapten of the present invention retains the characteristic structure of etomidate to the greatest extent, and has an active group that can be coupled with a carrier protein, and can be used as an antigenic determinant cluster; the artificial etomidate antigen prepared further can be immunized to obtain anti-etomidate antibodies with high affinity, high sensitivity and strong specificity, and the titer of the immune serum obtained by immunizing New Zealand white rabbits is as high as 1:90000, which can be used for rapid and accurate immunodetection and immunoanalysis of etomidate. BRIEF DESCRIPTION OF THE DRAWINGS
[0065] Figure 1 This is the reaction formula for preparing the etomidate artificial antigen of the present invention.
[0066] Wherein, DMF represents N,N-dimethylformamide, THF represents tetrahydrofuran, MeOH represents anhydrous methanol, BGG represents bovine gamma globulin, and Et3N represents triethylamine, and the same applies hereinafter.
[0067] Figure 2 This is a liquid chromatogram of the etomidate artificial hapten I prepared in Example 1 of the present invention.
[0068] Among them, the horizontal axis of the spectrum is time, the unit is min; the vertical axis is the response value, the unit is mAU.
[0069] Figure 3 This is the mass spectrum of the etomidate artificial hapten I prepared in Example 1 of the present invention.
[0070] Among them, RelativeAbundance represents relative abundance; m / z represents charge-to-mass ratio.
[0071] Figure 4 These are ultraviolet scanning images of bovine immunoglobulin, etomidate artificial hapten I, and etomidate artificial antigen II.
[0072] Wherein, Abs represents the UV-visible absorption spectrum, and WL (nm) represents the wavelength (nm).
[0073] Figure 5 This is the reaction formula for the preparation of etomidate artificial antigen IV in comparative example 1.
[0074] Wherein, BSA represents bovine serum albumin, DCC represents N,N'-dicyclohexylcarbodiimide, and the same applies hereinafter.
[0075] Figure 6 This is the reaction formula for the preparation of etomidate artificial antigen V in comparative example 2.
[0076] Figure 7 This is the reaction formula for the preparation of etomidate artificial antigen VI in comparative example 3.
[0077] Figure 8 This is the reaction formula for the preparation of etomidate artificial antigen VII in comparative example 4.
[0078] Fig. 9 This is the reaction formula for the preparation of etomidate artificial antigen VIII in comparative example 5.
[0079] Fig.10 This is the reaction formula for the preparation of etomidate artificial antigen IX in comparative example 6.
[0080] Fig.11 This is the reaction formula for the preparation of etomidate artificial antigen X in comparative example 7. DETAILED DESCRIPTION
[0081] The technical solution of the present invention is further described in detail below in conjunction with the accompanying drawings and specific implementation methods, but the protection scope of the present invention is not limited thereto.
[0082] Example 1
[0083] A method for preparing etomidate artificial antigen II (reaction formula as shown in Figure 1 As shown), comprising the following steps:
[0084] (1) Preparation of artificial hapten I:
[0085] ① Dissolve 500 mg of etomidate in 5.6 ml of tetrahydrofuran and 6.8 ml of anhydrous methanol, add 30 ml of 1N sodium hydroxide aqueous solution, react with rapid stirring at room temperature for 4 hours, adjust pH to 4-5 with 1N hydrochloric acid, extract with 30 ml×3 of dichloromethane, combine the organic phases, dry with anhydrous sodium sulfate, filter, and dry to obtain 460 mg of white solid A;
[0086] The white solid A was subjected to TLC detection. The chromatographic solution was 95% vol ethanol: 1,4-dioxane: dichloromethane: ammonia water in a volume ratio of 8:1:10:1. The product Rf was 0.4.
[0087] ② Dissolve 460 mg of white solid A in 30 ml of anhydrous methanol, slowly add 0.69 ml of 98% concentrated sulfuric acid, reflux at 68°C for 18 hours, add 1.173 g of solid sodium bicarbonate to neutralize after the reaction, adjust to pH ≈ 8, filter, dry the filtrate, add 30 ml × 3 tetrahydrofuran to extract, dry with anhydrous sodium sulfate, filter, and dry to obtain 390 mg of white solid B;
[0088] The white solid product B was subjected to TLC detection. The chromatographic solution was 95 vol% ethanol: 1,4-dioxane: dichloromethane: ammonia water in a volume ratio of 8:1:10:1, and the product Rf was 0.9.
[0089] ③ Dissolve 390 mg (1.696 mmol) of white solid B in 40 ml of anhydrous tetrahydrofuran, add 129 mg (3.392 mmol) of anhydrous lithium aluminum hydride, protect with nitrogen, and reflux at 68°C for 18 hours; after the reaction, adjust the pH to 8 with 30 wt% sodium hydroxide aqueous solution, filter and dry to obtain 375 mg (1.856 mmol) of white oil C;
[0090] The white oily product C was subjected to TLC detection. The chromatographic solution was 95% ethanol: 1,4-dioxane: dichloromethane: ammonia water in a volume ratio of 8:1:10:1. The product Rf was 0.7.
[0091] ④ Dissolve the obtained 375 mg (1.856 mmol) of white oily product C in 50 ml of anhydrous pyridine, add 371 mg (3.71 mmol) of succinic anhydride, and reflux at 100° C. for 20 hours; after the reaction, distill under reduced pressure and purify by thin layer chromatography to obtain 160 mg (0.530 mmol) of etomidate artificial hapten I, with anhydrous ethanol as the solvent and eluent;
[0092] The etomidate artificial hapten I was subjected to TLC detection, the chromatographic solution was 95 vol% ethanol:1,4-dioxane:dichloromethane:ammonia water in a volume ratio of 8:1:10:1, and the product Rf was 0.4.
[0093] The chromatographic solution used in the thin layer chromatography method was 95 vol% ethanol: 1,4-dioxane: dichloromethane: ammonia water = 8: 1: 10: 1, and the product Rf = 0.4.
[0094] The liquid chromatogram of etomidate artificial hapten I is shown in Figure 2 (UV detector, wavelength 285nm), the mass spectrum of etomidate hapten I is shown in Figure 3 .
[0095] from Figure 2 It can be seen that the purity of the purified etomidate artificial hapten reaches more than 99.9%. Figure 3 It can be seen that the mass-to-charge ratio (m / z) of the molecular ion peak of the etomidate artificial hapten obtained in this example is 303.29, which is consistent with its theoretical molecular weight of 302, and the mass-to-charge ratios (m / z) of its other three main fragment ion peaks are 172.11, 202.11, and 226.29, respectively, which are consistent with the theoretical molecular weights of its three main fragments of 171, 201, and 225. Based on the above data, it can be preliminarily determined that the final compound obtained in step ④ is the etomidate artificial hapten I designed by the present invention.
[0096] (2) Preparation of etomidate artificial antigen II:
[0097] ⑤ Place 160 mg (0.530 mmol) of etomidate artificial hapten in a 50 ml round-bottom flask, add 8 ml of N,N-dimethylformamide (DMF), then add 88 ul (0.636 mmol) of triethylamine, place in an ice bath and stir for 30 min, then add 89 ul (0.689 mmol) of isobutyl chloroformate, stir in an ice bath for 2 h, centrifuge after the reaction is completed, take the supernatant and set aside.
[0098] ⑥ Weigh 14.5 g (0.0405 mol) of disodium hydrogen phosphate dodecahydrate, 43.875 g (0.75 mol) of sodium chloride, and 1.495 g (0.00958 mol) of sodium dihydrogen phosphate dihydrate, dissolve them in deionized water to make up to 5.0 L to obtain 0.01 M PBS buffer solution with a pH of 7.4.
[0099] ⑦ Weigh 0.2 g of bovine immunoglobulin G and dissolve it in 40 ml of the PBS buffer prepared in step ⑥ to obtain a bovine immunoglobulin G solution with a concentration of 5 mg / ml.
[0100] ⑧ Under rapid stirring, slowly add the supernatant of step ⑤ to the bovine immunoglobulin G solution, the volume ratio of the supernatant to the bovine immunoglobulin G solution is 1:5, and the obtained mixture is stored at 4°C overnight to obtain an artificial antigen mixture.
[0101] ⑨ The artificial antigen mixture was transferred into a dialysis bag and dialyzed 9 times with the PBS buffer in step ⑥. After the dialysis, the supernatant was centrifuged to obtain etomidate artificial antigen II: etomidate-bovine gamma globulin conjugate. The UV scanning images of etomidate artificial antigen II before and after preparation are shown in Figure 4 .
[0102] Figure 4 In the figure, curve a is the UV scanning graph of etomidate artificial hapten I, curve b is the UV scanning graph of etomidate artificial antigen II, and curve c is the UV scanning graph of bovine gamma globulin. The maximum absorption wavelength of etomidate artificial hapten I is 285nm, the maximum absorption wavelength of bovine gamma globulin is 280nm, and the maximum absorption wavelength of etomidate artificial antigen II is 273nm. Compared with etomidate hapten I and bovine gamma globulin, the maximum absorption wavelength of etomidate artificial antigen II changes significantly, indicating that etomidate hapten I is successfully coupled with bovine gamma globulin.
[0103] Comparative Example 1
[0104] Preparation method of etomidate artificial antigen IV (reaction formula as shown in Figure 5 ), including the following steps:
[0105] (1) Preparation of etomidate artificial hapten III:
[0106] ① Dissolve 500 mg of etomidate in 5.6 ml of tetrahydrofuran and 6.8 ml of anhydrous methanol, add 30 ml of 1N sodium hydroxide aqueous solution, react at room temperature with rapid stirring for 4 hours, adjust pH to 4-5 with 1N hydrochloric acid, extract with 30 ml×3 dichloromethane, combine the organic phases, dry with anhydrous sodium sulfate, filter, and dry to obtain 448 mg of white solid A;
[0107] The white solid A was subjected to TLC detection. The chromatographic solution was 95% ethanol: 1,4-dioxane: dichloromethane: ammonia water = 8: 1: 10: 1. The product Rf = 0.4.
[0108] ② The white solid A was purified by thin layer chromatography to obtain 356 mg of etomidate hapten III;
[0109] The chromatography liquid was 95% ethanol:1,4-dioxane:dichloromethane:ammonia water=8:1:10:1, the product Rf=0.4, and the solvent and eluent were anhydrous ethanol.
[0110] (2) Preparation of etomidate artificial antigen IV:
[0111] ③ Take 100 mg (0.463 mmol) of etomidate hapten III in a 50 ml round-bottom flask, add 5 ml of N,N-dimethylformamide (DMF), then add 80 mg (0.695 mmol) of N-hydroxysuccinimide (NHS) and 143 mg (0.695 mmol) of cyclohexylcarbodiimide (DCC), stir at room temperature for overnight reaction, centrifuge and take the supernatant after the reaction is completed, and set aside.
[0112] ④ Weigh 14.5 g (0.0405 mol) of disodium hydrogen phosphate dodecahydrate, 43.875 g (0.75 mol) of sodium chloride, and 1.495 g (0.00958 mol) of sodium dihydrogen phosphate dihydrate, dissolve them in deionized water to make up to 5.0 L to obtain 0.01 M PBS buffer solution with a pH of 7.4.
[0113] ⑤ Weigh 0.125 g of bovine serum albumin and dissolve it in 25 ml of the PBS buffer prepared in step ④ to obtain a bovine serum albumin solution with a concentration of 5 mg / ml.
[0114] ⑥ Under rapid stirring, slowly add the supernatant of step ③ to the bovine serum albumin solution, the volume ratio of the supernatant to the bovine serum albumin solution is 1:5, and the obtained mixture is stored at 4°C overnight to obtain an artificial antigen mixture.
[0115] ⑦ Transfer the artificial antigen mixture into a dialysis bag and dialyze it 9 times with the PBS buffer in step ④. After the dialysis, centrifuge and take the supernatant to obtain artificial antigen IV: etomidate-bovine serum protein conjugate.
[0116] Comparative Example 2
[0117] This embodiment provides a method for preparing an etomidate artificial antigen V (reaction formula as shown in Figure 6 ), including the following steps:
[0118] (1) Preparation of etomidate artificial hapten III:
[0119] ①-② are the same as Comparative Example 1.
[0120] (2) Preparation of etomidate artificial antigen V:
[0121] Bovine immunoglobulin gamma was used as a carrier to couple with the etomidate artificial hapten III, and the coupling steps ③-⑦ were the same as those in comparative example 1 to obtain the etomidate artificial antigen V.
[0122] Comparative Example 3
[0123] This embodiment provides a method for preparing an etomidate artificial antigen VI (reaction formula as shown in Figure 7 ), including the following steps:
[0124] (1) Preparation of etomidate artificial hapten III:
[0125] ①-② are the same as Comparative Example 1.
[0126] (2) Preparation of etomidate artificial antigen VI:
[0127] ③ Weigh 100 mg (0.463 mmol) of etomidate artificial hapten III into a 50 ml round-bottom flask, add 5 ml N,N-dimethylformamide (DMF), then add 77 ul (0.556 mmol) of triethylamine, stir in an ice bath for 30 min, then add 76 ul (0.602 mmol) of isobutyl chloroformate, continue stirring in an ice bath for 2 h, centrifuge after the reaction is completed, take the supernatant and set aside.
[0128] ④ Weigh 14.5 g (0.0405 mol) of disodium hydrogen phosphate dodecahydrate, 43.875 g (0.75 mol) of sodium chloride, and 1.495 g (0.00958 mol) of sodium dihydrogen phosphate dihydrate, dissolve them in deionized water to make up to 5.0 L to obtain 0.01 M PBS buffer solution with a pH of 7.4.
[0129] ⑤ Weigh 0.125 g of bovine serum albumin and dissolve it in 25 ml of the PBS buffer prepared in step ④ to obtain a bovine serum albumin solution with a concentration of 5 mg / ml.
[0130] ⑥-⑦ are the same as comparative example 1; etomidate artificial antigen VI is obtained.
[0131] Comparative Example 4
[0132] This embodiment provides a method for preparing an etomidate artificial antigen VII (reaction formula as shown in Figure 8 ), including the following steps:
[0133] (1) Preparation of etomidate artificial hapten III:
[0134] ①②Same as Comparative Example 1.
[0135] (2) Preparation of etomidate artificial antigen:
[0136] Bovine immunoglobulin gamma was used as a carrier to couple with the etomidate artificial hapten III, and the coupling steps ③-⑦ were the same as those in comparative example ③ to obtain the etomidate artificial antigen VII.
[0137] Comparative Example 5
[0138] This embodiment provides a method for preparing an etomidate artificial antigen VIII (reaction formula as shown in Fig. 9 ), including the following steps:
[0139] (1) Preparation of etomidate artificial hapten I:
[0140] ①-④ are the same as in Example 1.
[0141] (2) Preparation of etomidate artificial antigen VIII:
[0142] ⑤ Weigh 160 mg (0.537 mmol) of etomidate artificial hapten I into a 50 ml round-bottom flask, add 8 ml of N,N-dimethylformamide (DMF), then add 93 mg (0.806 mmol) of N-hydroxysuccinimide (NHS) and 166 mg (0.806 mmol) of cyclohexylcarbodiimide (DCC), stir at room temperature for 18 hours, centrifuge after the reaction, take the supernatant and set aside.
[0143] ⑥ Weigh 14.5 g of disodium hydrogen phosphate dodecahydrate, 43.875 g of sodium chloride, and 1.495 g of sodium dihydrogen phosphate dihydrate, and dissolve them in deionized water to make up to 5.0 L to obtain 0.01 M PBS buffer solution with a pH of 7.4.
[0144] ⑦ Weigh 0.2g of bovine serum albumin and dissolve it in 40ml of PBS buffer to obtain a 5mg / ml bovine serum albumin solution.
[0145] ⑧ Under rapid stirring, slowly add the supernatant to the bovine serum albumin solution, the volume ratio of the supernatant to the bovine serum albumin solution is 1:5, and the obtained mixture is stored at 4°C overnight to obtain an artificial antigen mixture.
[0146] ⑨ Move the artificial antigen mixture into a dialysis bag and dialyze it 9 times with the above-mentioned PBS buffer. Centrifuge after dialysis and take the supernatant to obtain etomidate artificial antigen VIII.
[0147] Comparative Example 6
[0148] This invention implements a method for preparing an etomidate artificial antigen IX (reaction formula as shown in Fig.10 ), including the following steps:
[0149] (1) Preparation of etomidate artificial hapten I:
[0150] ①-④ are the same as in Example 1.
[0151] (2) Preparation of etomidate artificial antigen IX:
[0152] Bovine immunoglobulin gamma was used as a carrier to couple with the etomidate artificial hapten I, and the coupling steps were the same as those in comparative example 5 to obtain the etomidate artificial antigen IX.
[0153] Comparative Example 7
[0154] This invention implements a method for preparing an etomidate artificial antigen X (reaction formula as shown in Fig.11 ), including the following steps:
[0155] (1) Preparation of etomidate artificial hapten I:
[0156] ①-④ are the same as in Example 1.
[0157] (2) Preparation of etomidate artificial antigen X:
[0158] Bovine serum albumin was used as a carrier to couple with the etomidate artificial hapten I, and the coupling steps were the same as those in Example 1 to obtain the etomidate artificial antigen X.
[0159] Test example: Performance determination of etomidate artificial antigen
[0160] (1) Identification of etomidate artificial antigen:
[0161] Molar absorption coefficient ε: Prepare etomidate artificial hapten solutions with concentrations of 0μg / ml, 5μg / ml, 10μg / ml, 20μg / ml, 30μg / ml, and 40μg / ml using PBS buffer. The maximum absorption wavelength of etomidate hapten is 285nm as shown in the UV scanning diagram. Measure the absorbance at 285nm, and make parallel samples for each concentration. The calculation formula for the molar absorption coefficient (i.e., molar absorption coefficient) is: ε = absorbance / molar concentration.
[0162] Determination of protein concentration of conjugate: Prepare 1 ml of bovine immunoglobulin solution with concentrations of 0 μg / ml, 10 μg / ml, 20 μg / ml, 30 μg / ml, 40 μg / ml, 60 μg / ml, 80 μg / ml, 100 μg / ml, and 120 μg / ml with PBS buffer, add 3 ml of Coomassie Brilliant Blue staining solution, mix immediately, warm in a 30°C water bath for 5 minutes, make parallel samples for each concentration, measure the absorbance at 655 nm, and draw a curve of the relationship between protein concentration and absorbance. Dilute the etomidate artificial antigen solution (prepared with PBS buffer) in a certain proportion, measure the absorbance of the etomidate artificial antigen at 655 nm, and read the corresponding protein concentration value of the etomidate artificial antigen solution from the curve.
[0163] Coupling ratio determination: prepare 100 μg / ml bovine immunoglobulin PBS solution, dilute the conjugate (i.e., etomidate artificial antigen) to 100 μg / ml with PBS, measure the absorbance value A1 at 273 nm, and measure the absorbance value A2 with PBS as blank. The coupling ratio γ is: γ=[(A1-A2) / ε] / (100×10 -3 / 150000).
[0164] Where ε is the molar absorption coefficient (L / mol), 150000 is the molecular weight of bovine gamma globulin, and 100×10 -3is the concentration of bovine immunoglobulin (g / L).
[0165] When bovine serum albumin is used as a carrier, the coupling ratio is calculated as follows: γ = [(A1-A2) / ε] / (100×10 -3 / 65000); wherein 65000 is the molecular weight of bovine serum albumin.
[0166] The coupling ratios of the etomidate artificial antigens and the molar absorption coefficients of the corresponding haptens are shown in Table 1.
[0167] Table 1 Coupling ratio and molar absorption coefficient of each etomidate artificial antigen
[0168] serial number Artificial Antigen Coupling ratio Conjugate protein concentration Molar Absorption Coefficient Example 1 Ⅱ 24 3.254mg / ml 4025.66 Comparative Example 1 Ⅳ 12 2.134mg / ml 4118.38 Comparative Example 2 Ⅴ 5 0.534mg / ml 4118.38 Comparative Example 3 Ⅵ 14 2.226mg / ml 4118.38 Comparative Example 4 Ⅶ 18 2.252mg / ml 4118.38 Comparative Example 5 Ⅷ 3 0.189mg / ml 4025.66 Comparative Example 6 Ⅸ 28 3.568mg / ml 4025.66 Comparative Example 7 Ⅹ 7 1.088mg / ml 4025.66
[0169] As can be seen from Table 1, the structure of the artificial hapten, the activation method of the artificial hapten and the structure of the carrier protein all have an impact on the binding ratio when the artificial hapten is cross-linked with the carrier protein.
[0170] (2) Animal immunization
[0171] Each prepared etomidate artificial antigen was used to immunize New Zealand white rabbits, and the titer of the obtained immune serum was tested by ELISA method. The test results are shown in Table 2.
[0172] Table 2 The titer test results of each immune serum
[0173] serial number Etomidate artificial antigen Immune serum titer Example 1 Ⅱ 1:90000 Comparative Example 1 Ⅳ 1:15000 Comparative Example 2 Ⅴ / Comparative Example 3 Ⅵ 1:20000 Comparative Example 4 Ⅶ 1:3400 Comparative Example 5 Ⅷ 1:8000 Comparative Example 6 Ⅸ / Comparative Example 7 Ⅹ 1:1600
[0174] As can be seen from Table 2, compared with Example 1, the titers of the immune serum obtained by immunizing animals with the etomidate artificial antigens in each comparative example are all low and cannot be used in immunoassays. Among them, the etomidate artificial antigen V obtained in Comparative Example 2 immediately showed a large amount of precipitation during the dialysis process, and the etomidate artificial antigen IX obtained in Comparative Example 6 was relatively turbid, and a large amount of precipitation appeared after cryopreservation, and the stability was very poor, so it could not be used as an immune antigen. The immune serum obtained by immunizing animals with the etomidate artificial antigen II had a titer of 1:90000, which can be fully used in immunoassays, and can provide a more convenient, rapid and accurate way for the detection of etomidate.
Claims
1. An artificial hapten of etomidate, characterized in that: Its molecular structure is shown in Ⅰ:
2. The method for preparing the artificial hapten of etomidate according to claim 1, characterized in that: The method comprises the following steps: (1) performing a hydrolysis reaction between etomidate and an alkaline solution, and then adjusting the pH value to an acidic state to obtain a compound represented by formula A; (2) the compound represented by formula A is subjected to an esterification reaction with methanol to obtain a compound represented by formula B; (3) The compound represented by formula B is subjected to a reduction reaction with lithium aluminum hydride to obtain a compound represented by formula C; (4) subjecting the compound represented by formula C to a substitution reaction with succinic anhydride to obtain the etomidate artificial hapten represented by formula I; The reaction formula of the method is as follows:
3. The method according to claim 2, characterized in that In the step (1), the alkaline solution is an aqueous sodium hydroxide solution; In the step (2), the catalyst for the esterification reaction is concentrated sulfuric acid; In the step (3), the molar ratio of the compound represented by formula B to lithium aluminum hydride is 1:1.5-3; In the step (4), the molar ratio of the compound represented by formula C to succinic anhydride is 1:1.5-2.
5.
4. An etomidate artificial antigen, characterized in that: Its molecular structure is shown in II: In formula (II), BGG is bovine immunoglobulin G.
5. The method for preparing the etomidate artificial antigen according to claim 4, characterized in that: The method comprises: combining the etomidate artificial hapten shown in formula I of claim 1 with bovine immunoglobulin G by a mixed anhydride method to obtain the etomidate artificial antigen shown in formula II.
6. The method for preparing the etomidate artificial antigen according to claim 5, characterized in that: The method comprises the following steps: (a) the artificial hapten of etomidate represented by formula I, isobutyl chloroformate and triethylamine are reacted in DMF solvent at 0 to 5° C. with stirring for 2 to 4 hours, and after the reaction is completed, the supernatant is collected by centrifugation; The molar ratio of the etomidate artificial hapten represented by formula I, isobutyl chloroformate, and triethylamine is 1:1-1.5:1-1.5; (b) adding the supernatant dropwise to the bovine immunoglobulin solution, and placing the resulting mixture at 3-5° C. overnight, dialyzing and centrifuging to obtain the supernatant to obtain the etomidate artificial antigen shown in formula II.
7. The method for preparing the etomidate artificial antigen according to claim 6, characterized in that: In the step (b), the concentration of the bovine immunoglobulin G solution is 5 mg / mL, and the volume ratio of the supernatant to the bovine immunoglobulin G solution is 1:5-6.
8. Use of the etomidate hapten according to claim 1 or the etomidate artificial antigen according to claim 4 in the preparation of anti-etomidate antibodies.
